Technology
Health
Biotechnology

Celldex

$3.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.07 (2.25%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Celldex and other stocks, options, ETFs, and crypto commission-free!

About

Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Read More Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Employees
137
Headquarters
Hampton, New Jersey
Founded
1983
Market Cap
40.85M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
253.37K
High Today
$3.23
Low Today
$3.12
Open Price
$3.12
Volume
69.57K
52 Week High
$11.62
52 Week Low
$2.75

Collections

Technology
Health
Biotechnology
Therapy
Cancer Prevention
US
North America

News

Yahoo FinanceMay 7

Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of 0.88% and 13.10%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

447
Yahoo FinanceMay 7

Celldex Provides Corporate Update and Reports First Quarter 2019 Results

HAMPTON, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (CLDX) today reported business and financial highlights for the first quarter ended March 31, 2019. “Celldex presented positive data across multiple programs at AACR in April, including from our promising CDX-1140 program,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. “We have successfully cleared a critical hurdle for CD40 agonists, reaching dose levels with good systemic exposure...

101
NasdaqMay 2

Celldex Therapeutics (CLDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Celldex Therapeutics (CLDX) is expected to deliver a year-over-year increase in earnings on lower revenues when i t report s results for the quarter ended March 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

226

Earnings

-$1.40
-$0.95
-$0.49
-$0.04
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 8, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.